Items per page
Sort by

Send to:

Choose Destination

Results: 12


Variegated clonality and rapid emergence of new molecular lesions in xenografts of acute lymphoblastic leukemia are associated with drug resistance.

Nowak D, Liem NL, Mossner M, Klaum├╝nzer M, Papa RA, Nowak V, Jann JC, Akagi T, Kawamata N, Okamoto R, Thoennissen NH, Kato M, Sanada M, Hofmann WK, Ogawa S, Marshall GM, Lock RB, Koeffler HP.

Exp Hematol. 2015 Jan;43(1):32-43.e1-35. doi: 10.1016/j.exphem.2014.09.007. Epub 2014 Oct 29.


A pre-clinical model of resistance to induction therapy in pediatric acute lymphoblastic leukemia.

Samuels AL, Beesley AH, Yadav BD, Papa RA, Sutton R, Anderson D, Marshall GM, Cole CH, Kees UR, Lock RB.

Blood Cancer J. 2014 Aug 1;4:e232. doi: 10.1038/bcj.2014.52.


Disparate in vivo efficacy of FTY720 in xenograft models of Philadelphia positive and negative B-lineage acute lymphoblastic leukemia.

Wallington-Beddoe CT, Don AS, Hewson J, Qiao Q, Papa RA, Lock RB, Bradstock KF, Bendall LJ.

PLoS One. 2012;7(5):e36429. doi: 10.1371/journal.pone.0036429. Epub 2012 May 3. Erratum in: PLoS One. 2012;7(8). doi: 10.1371/annotation/d7342840-682b-4ee2-bb41-7b41aa5dedf7.


Validation of a mouse xenograft model system for gene expression analysis of human acute lymphoblastic leukaemia.

Samuels AL, Peeva VK, Papa RA, Firth MJ, Francis RW, Beesley AH, Lock RB, Kees UR.

BMC Genomics. 2010 Apr 21;11:256. doi: 10.1186/1471-2164-11-256.


Methotrexate and aminopterin exhibit similar in vitro and in vivo preclinical activity against acute lymphoblastic leukaemia and lymphoma.

Kang MH, Harutyunyan N, Hall CP, Papa RA, Lock RB.

Br J Haematol. 2009 May;145(3):389-93. doi: 10.1111/j.1365-2141.2009.07631.x. Epub 2009 Mar 7.


A xenograft model of infant leukaemia reveals a complex MLL translocation.

Henderson MJ, Choi S, Beesley AH, Baker DL, Wright D, Papa RA, Murch A, Campbell LJ, Lock RB, Norris MD, Haber M, Kees UR.

Br J Haematol. 2008 Mar;140(6):716-9. doi: 10.1111/j.1365-2141.2007.06966.x. Epub 2008 Jan 23. No abstract available.


Preclinical chemotherapeutic tumor models of common childhood cancers: solid tumors, acute lymphoblastic leukemia, and disseminated neuroblastoma.

Morton CL, Papa RA, Lock RB, Houghton PJ.

Curr Protoc Pharmacol. 2007 Dec;Chapter 14:Unit14.8. doi: 10.1002/0471141755.ph1408s39.


A role for altered microtubule polymer levels in vincristine resistance of childhood acute lymphoblastic leukemia xenografts.

Ong V, Liem NL, Schmid MA, Verrills NM, Papa RA, Marshall GM, Mackenzie KL, Kavallaris M, Lock RB.

J Pharmacol Exp Ther. 2008 Feb;324(2):434-42. Epub 2007 Nov 6.


Divergent mechanisms of glucocorticoid resistance in experimental models of pediatric acute lymphoblastic leukemia.

Bachmann PS, Gorman R, Papa RA, Bardell JE, Ford J, Kees UR, Marshall GM, Lock RB.

Cancer Res. 2007 May 1;67(9):4482-90.


Preclinical testing of antileukemic drugs using an in vivo model of systemic disease.

Lock RB, Liem NL, Papa RA.

Methods Mol Med. 2005;111:323-34.


Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies.

Liem NL, Papa RA, Milross CG, Schmid MA, Tajbakhsh M, Choi S, Ramirez CD, Rice AM, Haber M, Norris MD, MacKenzie KL, Lock RB.

Blood. 2004 May 15;103(10):3905-14. Epub 2004 Feb 5.


A single amino acid is critical for the expression of B-cell epitopes on the helicase domain of the pestivirus NS3 protein.

Brown LM, Papa RA, Frost MJ, Mackintosh SG, Gu X, Dixon RJ, Shannon AD.

Virus Res. 2002 Mar 20;84(1-2):111-24.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk